Novel approaches to inhibiting HIV-1 replication

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 119-141

  Adamson, Catherine S ^a   Freed, Eric O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Drug resistance; HIV 1 drug therapy; Retrovirus; Virus assembly; Virus entry

Indexed keywords

2,2' DITHIODIPYRIDINE; 4 VINYLPYRIDINE; AMPHOTERICIN B; AMPHOTERICIN B METHYL ESTER; ANTIRETROVIRUS AGENT; APTAMER; CELL PROTEIN; CHELATING AGENT; DIKETO ACID; DISULFIDE; ENFUVIRTIDE; ENZYME INHIBITOR; HOST RESTRICTION FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRASE; N ETHYLMALEIMIDE; N HYDROXYIMIDE; NAPHTHOQUINONE; PROTEINASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBONUCLEASE H; RIBONUCLEASE H INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIM 5ALPHA; TROPOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINOLOGOUS UREA; VIRUS PROTEIN;

CHROMATIN; COMBINATION CHEMOTHERAPY; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID RAFT; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIRUS ASSEMBLY; VIRUS CORE; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG DISCOVERY; HIV-1; HUMANS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73549107210     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.09.009     Document Type: Review

References (362)

1. Abdurahman S., Hoglund S., Goobar-Larsson L., and Vahlne A. Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release. J. Gen. Virol. 85 Pt 10 (2004) 2903-2913
2. Accola M.A., Hoglund S., and Gottlinger H.G. A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J. Virol. 72 3 (1998) 2072-2078
3. Accola M.A., Strack B., and Gottlinger H.G. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J. Virol. 74 12 (2000) 5395-5402
4. Adamson C.S., and Freed E.O. HIV-1 assembly, release and maturation. In: Jeang K.-T. (Ed). Advances in Pharmacolgy, HIV-1: Molecular Biology and Pathogenesis: Viral Mechansims vol. 55 (2007), Elsevier
5. Adamson C.S., and Freed E.O. Recent progress in antiretrovirals-lessons from resistance. Drug Discov. Today 13 9-10 (2008) 424-432
6. Adamson C.S., Ablan S.D., Boeras I., Goila-Gaur R., Soheilian F., Nagashima K., Li F., Salzwedel K., Sakalian M., Wild C.T., and Freed E.O. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J. Virol. 80 22 (2006) 10957-10971
7. Adamson C.S., Salzwedel K., and Freed E.O. Virus maturation as a new HIV-1 therapeutic target. Expert Opin. Ther. Targets 18 (2009) 895-908
8. Adamson C.S., Waki K., Ablan S.D., Salzwedel K., and Freed E.O. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J. Virol. 83 10 (2009) 4884-4894
9. Aiken C., and Chen C.H. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol. Med. 11 1 (2005) 31-36
10. Aloia R.C., Curtain C.C., and Jensen F.C. Membrane cholesterol and human immunodeficiency virus infectivity. In: Aloia R.C., and Curtain C.C. (Eds). Advances in Membrane Fluidity vol. 6 (1992), Wiley-Liss, Inc., New York 283-304
11. Aloia R.C., Tian H., and Jensen F.C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc. Natl. Acad. Sci. U.S.A. 90 11 (1993) 5181-5185
12. Anderson J., and Akkina R. TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. Mol. Ther. 12 4 (2005) 687-696
13. Anderson J., and Akkina R. Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum. Gene Ther. 19 3 (2008) 217-228
14. Anderson J.L., Campbell E.M., Wu X., Vandegraaff N., Engelman A., and Hope T.J. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J. Virol. 80 19 (2006) 9754-9760
15. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 4 (2004) 301-317
16. Arold S., Franken P., Strub M.P., Hoh F., Benichou S., Benarous R., and Dumas C. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 5 10 (1997) 1361-1372
17. Asaoka K., Ikeda K., Hishinuma T., Horie-Inoue K., Takeda S., and Inoue S. A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem. Biophys. Res. Commun. 338 4 (2005) 1950-1956
18. Baba M. Inhibitors of HIV-1 gene expression and transcription. Curr. Top. Med. Chem. 4 9 (2004) 871-882
19. Bannwarth S., and Gatignol A. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host. Curr. HIV Res. 3 1 (2005) 61-71
20. Barklis E., Alfadhli A., McQuaw C., Yalamuri S., Still A., Barklis R.L., Kukull B., and Lopez C.S. Characterization of the in vitro HIV-1 capsid assembly pathway. J. Mol. Biol. 387 (2009) 376-389
21. 2 with the C terminus of LEDGF/p75. J. Mol. Biol. 372 2 (2007) 407-421
22. Bartonova V., Igonet S., Sticht J., Glass B., Habermann A., Vaney M.C., Sehr P., Lewis J., Rey F.A., and Krausslich H.G. Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J. Biol. Chem. 283 46 (2008) 32024-32033
23. Beilhartz G.L., Wendeler M., Baichoo N., Rausch J., Le Grice S., and Gotte M. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition. J. Mol. Biol. 388 3 (2009) 462-474
24. Benjamin J., Ganser-Pornillos B.K., Tivol W.F., Sundquist W.I., and Jensen G.J. Three-dimensional structure of HIV-1 virus-like particles by electron cryotomography. J. Mol. Biol. 346 2 (2005) 577-588
25. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
26. Besnier C., Takeuchi Y., and Towers G. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. U.S.A. 99 18 (2002) 11920-11925
27. Betzi S., Restouin A., Opi S., Arold S.T., Parrot I., Guerlesquin F., Morelli X., and Collette Y. Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 Nef protein. Proc. Natl. Acad. Sci. U.S.A. 104 49 (2007) 19256-19261
28. Bhattacharya S., Zhang H., Debnath A.K., and Cowburn D. Solution structure of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid. J. Biol. Chem. 283 24 (2008) 16274-16278
29. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5 11 (2004) 1109-1115
30. Bieniasz P.D. Late budding domains and host proteins in enveloped virus release. Virology 344 1 (2006) 55-63
31. Bieniasz P.D. The cell biology of HIV-1 virion genesis. Cell Host Microbe 5 6 (2009) 550-558
32. Bishop K.N., Verma M., Kim E.Y., Wolinsky S.M., and Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4 12 (2008) e1000231
33. Bolinger C., and Boris-Lawrie K. Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome. Retrovirology 6 (2009) 8
34. Borkow G., Fletcher R.S., Barnard J., Arion D., Motakis D., Dmitrienko G.I., and Parniak M.A. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 36 11 (1997) 3179-3185
35. Borsetti A., Ohagen A., and Gottlinger H.G. The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J. Virol. 72 11 (1998) 9313-9317
36. Bour S., and Strebel K. The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect. 5 11 (2003) 1029-1039
37. Bour S., Schubert U., Peden K., and Strebel K. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?. J. Virol. 70 2 (1996) 820-829
38. Briggs J.A., Wilk T., Welker R., Krausslich H.G., and Fuller S.D. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22 7 (2003) 1707-1715
39. Briggs J.A., Simon M.N., Gross I., Krausslich H.G., Fuller S.D., Vogt V.M., and Johnson M.C. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11 7 (2004) 672-675
40. Briggs J.A., Grunewald K., Glass B., Forster F., Krausslich H.G., and Fuller S.D. The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure 14 1 (2006) 15-20
41. Briggs J.A., Riches J.D., Glass B., Bartonova V., Zanetti G., and Krausslich H.G. Structure and assembly of immature HIV. Proc. Natl. Acad. Sci. U.S.A. 106 27 (2009) 11090-11095
42. Brown D.A., and London E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol. 14 (1998) 111-136
43. Brown D.A., and Rose J.K. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68 3 (1992) 533-544
44. Brugger B., Glass B., Haberkant P., Leibrecht I., Wieland F.T., and Krausslich H.G. The HIV lipidome: a raft with an unusual composition. Proc. Natl. Acad. Sci. U.S.A. 103 8 (2006) 2641-2646
45. Brun S., Solignat M., Gay B., Bernard E., Chaloin L., Fenard D., Devaux C., Chazal N., and Briant L. VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability. Retrovirology 5 (2008) 57
46. Bryant M., and Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. U.S.A. 87 2 (1990) 523-527
47. Budihas S.R., Gorshkova I., Gaidamakov S., Wamiru A., Bona M.K., Parniak M.A., Crouch R.J., McMahon J.B., Beutler J.A., and Le Grice S.F. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res. 33 4 (2005) 1249-1256
48. Burniston M.T., Cimarelli A., Colgan J., Curtis S.P., and Luban J. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J. Virol. 73 10 (1999) 8527-8540
49. Butan C., Winkler D.C., Heymann J.B., Craven R.C., and Steven A.C. RSV capsid polymorphism correlates with polymerization efficiency and envelope glycoprotein content: implications that nucleation controls morphogenesis. J. Mol. Biol. 376 4 (2008) 1168-1181
50. Campbell S.M., Crowe S.M., and Mak J. Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS 16 17 (2002) 2253-2261
51. Campbell S., Gaus K., Bittman R., Jessup W., Crowe S., and Mak J. The raft-promoting property of virion-associated cholesterol, but not the presence of virion-associated Brij 98 rafts, is a determinant of human immunodeficiency virus type 1 infectivity. J. Virol. 78 19 (2004) 10556-10565
52. Campbell E.M., Perez O., Anderson J.L., and Hope T.J. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J. Cell Biol. 180 3 (2008) 549-561
53. Carl S., Daniels R., Iafrate A.J., Easterbrook P., Greenough T.C., Skowronski J., and Kirchhoff F. Partial "repair" of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection. J. Infect. Dis. 181 1 (2000) 132-140
54. Carlson L.A., Briggs J.A., Glass B., Riches J.D., Simon J.D., Johnson M.C., Muller B., Grunewald K., and Krausslich H.G. Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe 4 6 (2008) 592-599
55. Champoux J.J., and Schultz S.J. Ribonuclease H: properties, substrate specificity and roles in retroviral reverse transcription. FEBS J. 276 6 (2009) 1506-1516
56. Chan R., Uchil P.D., Jin J., Shui G., Ott D.E., Mothes W., and Wenk M.R. Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides. J. Virol. 82 22 (2008) 11228-11238
57. Chen L.F., Hoy J., and Lewin S.R. Ten years of highly active antiretroviral therapy for HIV infection. Med. J. Aust. 186 3 (2007) 146-151
58. Chen K., Bachtiar I., Piszczek G., Bouamr F., Carter C., and Tjandra N. Solution NMR characterizations of oligomerization and dynamics of equine infectious anemia virus matrix protein and its interaction with PIP2. Biochemistry 47 7 (2008) 1928-1937
59. Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., De Clercq E., and Debyser Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278 1 (2003) 372-381
60. Cherepanov P., Sun Z.Y., Rahman S., Maertens G., Wagner G., and Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat. Struct. Mol. Biol. 12 6 (2005) 526-532
61. Chertova E.N., Kane B.P., McGrath C., Johnson D.G., Sowder II R.C., Arthur L.O., and Henderson L.E. Probing the topography of HIV-1 nucleocapsid protein with the alkylating agent N-ethylmaleimide. Biochemistry 37 51 (1998) 17890-17897
62. Chesebro B., and Wehrly K. Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc. Natl. Acad. Sci. U.S.A. 76 1 (1979) 425-429
63. Cihlar T. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 85 (2010) 39-58
64. Ciuffi A., Llano M., Poeschla E., Hoffmann C., Leipzig J., Shinn P., Ecker J.R., and Bushman F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 11 12 (2005) 1287-1289
65. Cowan S., Hatziioannou T., Cunningham T., Muesing M.A., Gottlinger H.G., and Bieniasz P.D. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. U.S.A. 99 18 (2002) 11914-11919
66. Cristofaro J.V., Rausch J.W., Le Grice S.F., and DeStefano J.J. Mutations in the ribonuclease H active site of HIV-RT reveal a role for this site in stabilizing enzyme-primer-template binding. Biochemistry 41 36 (2002) 10968-10975
67. Das K., Bauman J.D., Clark Jr. A.D., Frenkel Y.V., Lewi P.J., Shatkin A.J., Hughes S.H., and Arnold E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U.S.A. 105 5 (2008) 1466-1471
68. Davies II J.F., Hostomska Z., Hostomsky Z., Jordan S.R., and Matthews D.A. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252 5002 (1991) 88-95
69. De Béthune M.-P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antiviral Res 85 (2010) 75-90
70. De Camilli P., Emr S.D., McPherson P.S., and Novick P. Phosphoinositides as regulators in membrane traffic. Science 271 5255 (1996) 1533-1539
71. De Matteis M.A., and Godi A. PI-loting membrane traffic. Nat. Cell Biol. 6 6 (2004) 487-492
72. De Rijck J., Vandekerckhove L., Gijsbers R., Hombrouck A., Hendrix J., Vercammen J., Engelborghs Y., Christ F., and Debyser Z. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J. Virol. 80 23 (2006) 11498-11509
73. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., McPhee D.A., Greenway A.L., Ellett A., Chatfield C., Lawson V.A., Crowe S., Maerz A., Sonza S., Learmont J., Sullivan J.S., Cunningham A., Dwyer D., Dowton D., and Mills J. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270 5238 (1995) 988-991
74. del Real G., Jimenez-Baranda S., Mira E., Lacalle R.A., Lucas P., Gomez-Mouton C., Alegret M., Pena J.M., Rodriguez-Zapata M., Alvarez-Mon M., Martinez A.C., and Manes S. Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200 4 (2004) 541-547
75. Delelis O., Carayon K., Saib A., Deprez E., and Mouscadet J.F. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 5 (2008) 114
76. Demirov D.G., and Freed E.O. Retrovirus budding. Virus Res. 106 2 (2004) 87-102
77. Demirov D.G., Ono A., Orenstein J.M., and Freed E.O. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc. Natl. Acad. Sci. U.S.A. 99 2 (2002) 955-960
78. Demirov D.G., Orenstein J.M., and Freed E.O. The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J. Virol. 76 1 (2002) 105-117
79. Diaz E., and Pfeffer S.R. TIP47: a cargo selection device for mannose 6-phosphate receptor trafficking. Cell 93 3 (1998) 433-443
80. Didierjean J., Isel C., Querre F., Mouscadet J.F., Aubertin A.M., Valnot J.Y., Piettre S.R., and Marquet R. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob. Agents Chemother. 49 12 (2005) 4884-4894
81. Doms R.W. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276 2 (2000) 229-237
82. Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Entry inhibitors, Antiviral Res. 85 (2010) 91-100
83. Dorfman T., Bukovsky A., Ohagen A., Hoglund S., and Gottlinger H.G. Functional domains of the capsid protein of human immunodeficiency virus type 1. J. Virol. 68 12 (1994) 8180-8187
84. Du L., Zhao Y., Chen J., Yang L., Zheng Y., Tang Y., Shen X., and Jiang H. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem. Biophys. Res. Commun. 375 1 (2008) 139-144
85. Emiliani S., Mousnier A., Busschots K., Maroun M., Van Maele B., Tempe D., Vandekerckhove L., Moisant F., Ben-Slama L., Witvrouw M., Christ F., Rain J.C., Dargemont C., Debyser Z., and Benarous R. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 280 27 (2005) 25517-25523
86. Emini E.A., and Fan H.Y. Immunological and pharmacological approaches to the control of retroviral infections. In: Coffin J.M., Hughes S.H., and Varmus H.E. (Eds). Retroviruses (1997), Cold Spring Harbor Laboratory Press
87. Engelman A., and Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 4 3 (2008) e1000046
88. Erickson-Viitanen S., Manfredi J., Viitanen P., Tribe D.E., Tritch R., Hutchison III C.A., Loeb D.D., and Swanstrom R. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5 6 (1989) 577-591
89. Ewart G.D., Mills K., Cox G.B., and Gage P.W. Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur. Biophys. J. 31 1 (2002) 26-35
90. Faure A., Calmels C., Desjobert C., Castroviejo M., Caumont-Sarcos A., Tarrago-Litvak L., Litvak S., and Parissi V. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res. 33 3 (2005) 977-986
91. Fitzon T., Leschonsky B., Bieler K., Paulus C., Schroder J., Wolf H., and Wagner R. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology 268 2 (2000) 294-307
92. Forshey B.M., von Schwedler U., Sundquist W.I., and Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76 11 (2002) 5667-5677
93. Forshey B.M., Shi J., and Aiken C. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J. Virol. 79 2 (2005) 869-875
94. Foster J.L., and Garcia J.V. Role of Nef in HIV-1 replication and pathogenesis. Adv. Pharmacol. 55 (2007) 389-409
95. Foster J.L., and Garcia J.V. HIV-1 Nef: at the crossroads. Retrovirology 5 (2008) 84
96. Freed E.O. HIV-1 and the host cell: an intimate association. Trends Microbiol. 12 4 (2004) 170-177
97. Freed E.O. HIV-1 Gag: flipped out for PI(4,5)P(2). Proc. Natl. Acad. Sci. U.S.A. 103 30 (2006) 11101-11102
98. Freed E.O., and Martin M.A. HIVs and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2007), Lippincott, Williams and Wilkins 2107-2185
99. Freed E.O., Orenstein J.M., Buckler-White A.J., and Martin M.A. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J. Virol. 68 8 (1994) 5311-5320
100. Fujii K., Hurley J.H., and Freed E.O. Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1. Nat. Rev. Microbiol. 5 12 (2007) 912-916
101. Fujii K., Munshi U.M., Ablan S.D., Demirov D.G., Soheilian F., Nagashima K., Stephen A.G., Fisher R.J., and Freed E.O. Functional role of Alix in HIV-1 replication. Virology (2009)
102. Fuller S.D., Wilk T., Gowen B.E., Krausslich H.G., and Vogt V.M. Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle. Curr. Biol. 7 10 (1997) 729-738
103. Fun A., van Maarseveen N.M., Maas R.E.M., and Nijhuis M. Resistance mutations in the viral protease alter bevirimat resistance patterns in vitro. "18th HIV Drug Resisatnce Workshop". Ft Myeres, Florida, USA (2009)
104. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., and Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66 11 (1992) 6489-6495
105. Gamble T.R., Vajdos F.F., Yoo S., Worthylake D.K., Houseweart M., Sundquist W.I., and Hill C.P. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87 7 (1996) 1285-1294
106. Gamble T.R., Yoo S., Vajdos F.F., von Schwedler U.K., Worthylake D.K., Wang H., McCutcheon J.P., Sundquist W.I., and Hill C.P. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278 5339 (1997) 849-853
107. Ganapathy V., Daniels T., and Casiano C.A. LEDGF/p75: a novel nuclear autoantigen at the crossroads of cell survival and apoptosis. Autoimmun. Rev. 2 5 (2003) 290-297
108. Ganser B.K., Li S., Klishko V.Y., Finch J.T., and Sundquist W.I. Assembly and analysis of conical models for the HIV-1 core. Science 283 5398 (1999) 80-83
109. Ganser-Pornillos B.K., von Schwedler U.K., Stray K.M., Aiken C., and Sundquist W.I. Assembly properties of the human immunodeficiency virus type 1 CA protein. J. Virol. 78 5 (2004) 2545-2552
110. Ganser-Pornillos B.K., Cheng A., and Yeager M. Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 131 1 (2007) 70-79
111. Ganser-Pornillos B.K., Yeager M., and Sundquist W.I. The structural biology of HIV assembly. Curr. Opin. Struct. Biol. 18 2 (2008) 203-217
112. Garrus J.E., von Schwedler U.K., Pornillos O.W., Morham S.G., Zavitz K.H., Wang H.E., Wettstein D.A., Stray K.M., Cote M., Rich R.L., Myszka D.G., and Sundquist W.I. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107 1 (2001) 55-65
113. Goffinet C., Allespach I., Homann S., Tervo H.M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., Krijnse-Locker J., Banting G., Krausslich H.G., Fackler O.T., and Keppler O.T. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5 3 (2009) 285-297
114. Goila-Gaur R., Demirov D.G., Orenstein J.M., Ono A., and Freed E.O. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. J. Virol. 77 11 (2003) 6507-6519
115. Gorelick R.J., Henderson L.E., Hanser J.P., and Rein A. Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence. Proc. Natl. Acad. Sci. U.S.A. 85 22 (1988) 8420-8424
116. Gorelick R.J., Nigida Jr. S.M., Bess Jr. J.W., Arthur L.O., Henderson L.E., and Rein A. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J. Virol. 64 7 (1990) 3207-3211
117. Gottlinger H.G., Sodroski J.G., and Haseltine W.A. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 86 15 (1989) 5781-5785
118. Gottlinger H.G., Dorfman T., Sodroski J.G., and Haseltine W.A. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. U.S.A. 88 8 (1991) 3195-3199
119. Graham D.R., Chertova E., Hilburn J.M., Arthur L.O., and Hildreth J.E. Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J. Virol. 77 15 (2003) 8237-8248
120. Greene W.C., Debyser Z., Ikeda Y., Freed E.O., Stephens E., Yonemoto W., Buckheit R.W., Este J.A., and Cihlar T. Novel targets for HIV therapy. Antiviral Res. 80 3 (2008) 251-265
121. Grzesiek S., Bax A., Clore G.M., Gronenborn A.M., Hu J.S., Kaufman J., Palmer I., Stahl S.J., and Wingfield P.T. The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nat. Struct. Biol. 3 4 (1996) 340-345
122. Grzesiek S., Stahl S.J., Wingfield P.T., and Bax A. The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Biochemistry 35 32 (1996) 10256-10261
123. Grzesiek S., Bax A., Hu J.S., Kaufman J., Palmer I., Stahl S.J., Tjandra N., and Wingfield P.T. Refined solution structure and backbone dynamics of HIV-1 Nef. Protein Sci. 6 6 (1997) 1248-1263
124. Guo X., Roldan A., Hu J., Wainberg M.A., and Liang C. Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J. Virol. 79 3 (2005) 1803-1812
125. Gupta R.K., Hue S., Schaller T., Verschoor E., Pillay D., and Towers G.J. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5 5 (2009) e1000443
126. Guyader M., Kiyokawa E., Abrami L., Turelli P., and Trono D. Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J. Virol. 76 20 (2002) 10356-10364
127. Hang J.Q., Rajendran S., Yang Y., Li Y., In P.W., Overton H., Parkes K.E., Cammack N., Martin J.A., and Klumpp K. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem. Biophys. Res. Commun. 317 2 (2004) 321-329
128. Hannoush R.N., Carriero S., Min K.L., and Damha M.J. Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells. Chembiochem 5 4 (2004) 527-533
129. Hare S., Shun M.C., Gupta S.S., Valkov E., Engelman A., and Cherepanov P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog. 5 1 (2009) e1000259
130. Harris R.S., and Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4 11 (2004) 868-877
131. Harris R.S., Petersen-Mahrt S.K., and Neuberger M.S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10 5 (2002) 1247-1253
132. Hatziioannou T., Cowan S., Von Schwedler U.K., Sundquist W.I., and Bieniasz P.D. Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 78 11 (2004) 6005-6012
133. Hatziioannou T., Perez-Caballero D., Yang A., Cowan S., and Bieniasz P.D. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc. Natl. Acad. Sci. U.S.A. 101 29 (2004) 10774-10779
134. Hayouka Z., Rosenbluh J., Levin A., Loya S., Lebendiker M., Veprintsev D., Kotler M., Hizi A., Loyter A., and Friedler A. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc. Natl. Acad. Sci. U.S.A. 104 20 (2007) 8316-8321
135. Himmel D.M., Sarafianos S.G., Dharmasena S., Hossain M.M., McCoy-Simandle K., Ilina T., Clark Jr. A.D., Knight J.L., Julias J.G., Clark P.K., Krogh-Jespersen K., Levy R.M., Hughes S.H., Parniak M.A., and Arnold E. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem. Biol. 1 11 (2006) 702-712
136. Hombrouck A., De Rijck J., Hendrix J., Vandekerckhove L., Voet A., De Maeyer M., Witvrouw M., Engelborghs Y., Christ F., Gijsbers R., and Debyser Z. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog. 3 3 (2007) e47
137. Hou Y., McGuinness D.E., Prongay A.J., Feld B., Ingravallo P., Ogert R.A., Lunn C.A., and Howe J.A. Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J. Biomol. Screen. 13 5 (2008) 406-414
138. Hout D.R., Gomez L.M., Pacyniak E., Miller J.M., Hill M.S., and Stephens E.B. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine. Virology 348 2 (2006) 449-461
139. Hout D.R., Gomez M.L., Pacyniak E., Gomez L.M., Fegley B., Mulcahy E.R., Hill M.S., Culley N., Pinson D.M., Nothnick W., Powers M.F., Wong S.W., and Stephens E.B. Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques. Virology 344 2 (2006) 541-559
140. Hu W.S., Rhodes T., Dang Q., and Pathak V. Retroviral recombination: review of genetic analyses. Front. Biosci. 8 (2003) d143-d155
141. Huang M., Orenstein J.M., Martin M.A., and Freed E.O. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69 11 (1995) 6810-6818
142. Hurley J.H., and Emr S.D. The ESCRT complexes: structure and mechanism of a membrane-trafficking network. Annu. Rev. Biophys. Biomol. Struct. 35 (2006) 277-298
143. Ivanov D., Stone J.R., Maki J.L., Collins T., and Wagner G. Mammalian SCAN domain dimer is a domain-swapped homolog of the HIV capsid C-terminal domain. Mol. Cell 17 1 (2005) 137-143
144. Javanbakht H., Yuan W., Yeung D.F., Song B., Diaz-Griffero F., Li Y., Li X., Stremlau M., and Sodroski J. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 353 1 (2006) 234-246
145. Jenkins L.M., Durell S.R., Maynard A.T., Stahl S.J., Inman J.K., Appella E., Legault P., and Omichinski J.G. Comparison of the specificity of interaction of cellular and viral zinc-binding domains with 2-mercaptobenzamide thioesters. J. Am. Chem. Soc. 128 36 (2006) 11964-11976
146. Jia B., Serra-Moreno R., Neidermyer W., Rahmberg A., Mackey J., Fofana I.B., Johnson W.E., Westmoreland S., and Evans D.T. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5 5 (2009) e1000429
147. Jochmans D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 134 1-2 (2008) 171-185
148. Jolly C., and Sattentau Q.J. Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity. J. Virol. 79 18 (2005) 12088-12094
149. Jouvenet N., Neil S.J., Zhadina M., Zang T., Kratovac Z., Lee Y., McNatt M., Hatziioannou T., and Bieniasz P.D. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83 4 (2009) 1837-1844
150. Kaletsky R.L., Francica J.R., Agrawal-Gamse C., and Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 106 8 (2009) 2886-2891
151. Kaplan A.H., Zack J.A., Knigge M., Paul D.A., Kempf D.J., Norbeck D.W., and Swanstrom R. Partial inhibition of the human immunodeficiency virus type 1 protease results in abbreant virus assembly and the formation of non-infectious particles. J. Virol. 67 (1993) 4050-4055
152. Kar A.K., Diaz-Griffero F., Li Y., Li X., and Sodroski J. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J. Virol. 82 23 (2008) 11669-11681
153. Keckesova Z., Ylinen L.M., and Towers G.J. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U.S.A. 101 29 (2004) 10780-10785
154. Kelly B.N., Kyere S., Kinde I., Tang C., Howard B.R., Robinson H., Sundquist W.I., Summers M.F., and Hill C.P. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 373 2 (2007) 355-366
155. Kestler III H.W., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., and Desrosiers R.C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65 4 (1991) 651-662
156. Khanna K.V., Whaley K.J., Zeitlin L., Moench T.R., Mehrazar K., Cone R.A., Liao Z., Hildreth J.E., Hoen T.E., Shultz L., and Markham R.B. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 109 2 (2002) 205-211
157. Kingston R.L., and Vogt V.M. Domain swapping and retroviral assembly. Mol. Cell 17 2 (2005) 166-167
158. Kirchhoff F., Greenough T.C., Brettler D.B., Sullivan J.L., and Desrosiers R.C. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332 4 (1995) 228-232
159. Klumpp K., and Mirzadegan T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr. Pharm. Des. 12 15 (2006) 1909-1922
160. Klumpp K., Hang J.Q., Rajendran S., Yang Y., Derosier A., Wong Kai In P., Overton H., Parkes K.E., Cammack N., and Martin J.A. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res. 31 23 (2003) 6852-6859
161. Knapp D.J.H.F., Huang S., and Harrington R. Stable prevelance of bevirimat-related Gag polymorphisms both before and after HAART exposure. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada (2009)
162. Krausslich H.G., Schneider H., Zybarth G., Carter C.A., and Wimmer E. Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J. Virol. 62 11 (1988) 4393-4397
163. Krausslich H.G., Facke M., Heuser A.M., Konvalinka J., and Zentgraf H. The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J. Virol. 69 6 (1995) 3407-3419
164. Kupzig S., Korolchuk V., Rollason R., Sugden A., Wilde A., and Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4 10 (2003) 694-709
165. Langelier C.R., Sandrin V., Eckert D.M., Christensen D.E., Chandrasekaran V., Alam S.L., Aiken C., Olsen J.C., Kar A.K., Sodroski J.G., and Sundquist W.I. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J. Virol. 82 23 (2008) 11682-11694
166. Lee C.H., Saksela K., Mirza U.A., Chait B.T., and Kuriyan J. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 85 6 (1996) 931-942
167. Lee S., Joshi A., Nagashima K., Freed E.O., and Hurley J.H. Structural basis for viral late-domain binding to Alix. Nat. Struct. Mol. Biol. 14 3 (2007) 194-199
168. Lee S.K., Harris J., and Swanstrom R. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an achilles heel in the virus life cycle. J. Virol. (2009)
169. Levin J.G., Guo J., Rouzina I., and Musier-Forsyth K. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog. Nucleic Acid Res. Mol. Biol. 80 (2005) 217-286
170. Li X., and Sodroski J. The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J. Virol. 82 23 (2008) 11495-11502
171. Li S., Hill C.P., Sundquist W.I., and Finch J.T. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407 6802 (2000) 409-413
172. Li F., Goila-Gaur R., Salzwedel K., Kilgore N.R., Reddick M., Matallana C., Castillo A., Zoumplis D., Martin D.E., Orenstein J.M., Allaway G.P., Freed E.O., and Wild C.T. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. U.S.A. 100 23 (2003) 13555-13560
173. Li Y., Li X., Stremlau M., Lee M., and Sodroski J. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 80 14 (2006) 6738-6744
174. Liang C., Hu J., Russell R.S., Roldan A., Kleiman L., and Wainberg M.A. Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J. Virol. 76 22 (2002) 11729-11737
175. Liang C., Hu J., Whitney J.B., Kleiman L., and Wainberg M.A. A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1. J. Virol. 77 3 (2003) 1772-1783
176. Liao Z., Cimakasky L.M., Hampton R., Nguyen D.H., and Hildreth J.E. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retroviruses 17 11 (2001) 1009-1019
177. Lifson J.D., Rossio J.L., Piatak Jr. M., Bess Jr. J., Chertova E., Schneider D.K., Coalter V.J., Poore B., Kiser R.F., Imming R.J., Scarzello A.J., Henderson L.E., Alvord W.G., Hirsch V.M., Benveniste R.E., and Arthur L.O. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retroviruses 20 7 (2004) 772-787
178. Liu F., Stephen A.G., Adamson C.S., Gousset K., Aman M.J., Freed E.O., Fisher R.J., and Burke Jr. T.R. Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists. Org. Lett. 8 22 (2006) 5165-5168
179. Liu F., Stephen A.G., Waheed A.A., Aman M.J., Freed E.O., Fisher R.J., and Burke Jr. T.R. SAR by oxime-containing peptide libraries: application to Tsg101 ligand optimization. Chembiochem 9 12 (2008) 2000-2004
180. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., Teo W., and Poeschla E.M. An essential role for LEDGF/p75 in HIV integration. Science 314 5798 (2006) 461-464
181. Lopez-Verges S., Camus G., Blot G., Beauvoir R., Benarous R., and Berlioz-Torrent C. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc. Natl. Acad. Sci. U.S.A. 103 40 (2006) 14947-14952
182. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. 81 3 (2007) 1054-1061
183. Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., and Goff S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73 6 (1993) 1067-1078
184. Luttge B.G., Shehu-Xhilaga M., Demirov D.G., Adamson C.S., Soheilian F., Nagashima K., Stephen A.G., Fisher R.J., and Freed E.O. Molecular characterization of feline immunodeficiency virus budding. J. Virol. 82 5 (2008) 2106-2119
185. Madani N., and Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72 12 (1998) 10251-10255
186. Maertens G.N., Cherepanov P., and Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J. Cell Sci. 119 Pt 12 (2006) 2563-2571
187. Malet I., Wirden M., Derache A., Simon A., Katlama C., Calvez V., and Marcelin A.G. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS 21 7 (2007) 871-873
188. Malim M.H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. Roy. Soc. Lond. B: Biol. Sci. 364 1517 (2009) 675-687
189. Mammano F., Ohagen A., Hoglund S., and Gottlinger H.G. Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J. Virol. 68 8 (1994) 4927-4936
190. Manes S., del Real G., Lacalle R.A., Lucas P., Gomez-Mouton C., Sanchez-Palomino S., Delgado R., Alcami J., Mira E., and Martinez A.C. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 1 2 (2000) 190-196
191. Margot N.A., Gibbs C.S., and Miller M.D. Phenotyphic susceptibility to bevirimat among HIV-infected patient isolates without prior exposure to bevirimat. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada (2009)
192. Marsden M.D., and Zack J.A. Eradication of HIV: current challenges and new directions. J. Antimicrob. Chemother. 63 1 (2009) 7-10
193. Marshall H.M., Ronen K., Berry C., Llano M., Sutherland H., Saenz D., Bickmore W., Poeschla E., and Bushman F.D. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2 12 (2007) e1340
194. Martin D.E., Salzwedel K., and Allaway G.P. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir. Chem. Chemother. 19 3 (2008) 107-113
195. Martin-Serrano J., Zang T., and Bieniasz P.D. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7 12 (2001) 1313-1319
196. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., and Pathak V.K. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81 13 (2007) 7099-7110
197. McCallister S., Lalezari J., Richmond G., Thompson M., Harrigan R., Martin D., Salzwedel K., and Allaway G. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
198. McDonald B., and Martin-Serrano J. No strings attached: the ESCRT machinery in viral budding and cytokinesis. J. Cell Sci. 122 Pt 13 (2009) 2167-2177
199. McNatt M.W., Zang T., Hatziioannou T., Bartlett M., Fofana I.B., Johnson W.E., Neil S.J., and Bieniasz P.D. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5 2 (2009) e1000300
200. Mehle A., Wilson H., Zhang C., Brazier A.J., McPike M., Pery E., and Gabuzda D. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81 23 (2007) 13235-13241
201. Melamed D., Mark-Danieli M., Kenan-Eichler M., Kraus O., Castiel A., Laham N., Pupko T., Glaser F., Ben-Tal N., and Bacharach E. The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release. J. Virol. 78 18 (2004) 9675-9688
202. Melikyan G.B. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 5 (2008) 111
203. Mervis R.J., Ahmad N., Lillehoj E.P., Raum M.G., Salazar F.H., Chan H.W., and Venkatesan S. The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J. Virol. 62 11 (1988) 3993-4002
204. Min B.S., Miyashiro H., and Hattori M. Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother. Res. 16 Suppl. 1 (2002) S57-S62
205. Mische C.C., Javanbakht H., Song B., Diaz-Griffero F., Stremlau M., Strack B., Si Z., and Sodroski J. Retroviral restriction factor TRIM5alpha is a trimer. J. Virol. 79 22 (2005) 14446-14450
206. Mitchell R.S., Katsura C., Skasko M.A., Fitzpatrick K., Lau D., Ruiz A., Stephens E.B., Margottin-Goguet F., Benarous R., and Guatelli J.C. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5 5 (2009) e1000450
207. Miyagi E., Andrew A.J., Kao S., and Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U.S.A. 106 8 (2009) 2868-2873
208. Miyazawa M., Tsuji-Kawahara S., and Kanari Y. Host genetic factors that control immune responses to retrovirus infections. Vaccine 26 24 (2008) 2981-2996
209. Moncunill G., Negredo E., Bosch L., Vilarrasa J., Witvrouw M., Llano A., Clotet B., and Este J.A. Evaluation of the anti-HIV activity of statins. AIDS 19 15 (2005) 1697-1700
210. Montal M. Vpu matchmakers as a therapeutic strategy for HIV infection. PLoS Pathog. 5 5 (2009) e1000246
211. Morcock D.R., Thomas J.A., Sowder II R.C., Henderson L.E., Crise B.J., and Gorelick R.J. HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Virology 375 1 (2008) 148-158
212. Morellet N., Druillennec S., Lenoir C., Bouaziz S., and Roques B.P. Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging. Protein Sci. 14 2 (2005) 375-386
213. Morikawa Y., Hockley D.J., Nermut M.V., and Jones I.M. Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly. J. Virol. 74 1 (2000) 16-23
214. Morita E., and Sundquist W.I. Retrovirus budding. Annu. Rev. Cell Dev. Biol. 20 (2004) 395-425
215. Munk C., Brandt S.M., Lucero G., and Landau N.R. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. U.S.A. 99 21 (2002) 13843-13848
216. Munro S. Lipid rafts: elusive or illusive?. Cell 115 4 (2003) 377-388
217. Munshi U.M., Kim J., Nagashima K., Hurley J.H., and Freed E.O. An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J. Biol. Chem. 282 6 (2007) 3847-3855
218. Nathans R., Cao H., Sharova N., Ali A., Sharkey M., Stranska R., Stevenson M., and Rana T.M. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26 10 (2008) 1187-1192
219. Neil S.J., Zang T., and Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 7177 (2008) 425-430
220. Nekhai S., and Jeang K.T. Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol. 1 (2006) 417-426
221. Newman J.L., Butcher E.W., Patel D.T., Mikhaylenko Y., and Summers M.F. Flexibility in the P2 domain of the HIV-1 Gag polyprotein. Protein Sci. 13 8 (2004) 2101-2107
222. Nguyen D.H., and Hildreth J.E. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74 7 (2000) 3264-3272
223. Nguyen D.H., and Taub D. CXCR4 function requires membrane cholesterol: implications for HIV infection. J. Immunol. 168 8 (2002) 4121-4126
224. Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res. 85 (2010) 59-74
225. Nisole S., Lynch C., Stoye J.P., and Yap M.W. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. U.S.A. 101 36 (2004) 13324-13328
226. Nowotny M., and Yang W. Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release. EMBO J. 25 9 (2006) 1924-1933
227. Nowotny M., Gaidamakov S.A., Crouch R.J., and Yang W. Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121 7 (2005) 1005-1016
228. Nowotny M., Gaidamakov S.A., Ghirlando R., Cerritelli S.M., Crouch R.J., and Yang W. Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell 28 2 (2007) 264-276
229. Okeoma C.M., Lovsin N., Peterlin B.M., and Ross S.R. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445 7130 (2007) 927-930
230. Okeoma C.M., Low A., Bailis W., Fan H.Y., Peterlin B.M., and Ross S.R. Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J. Virol. 83 8 (2009) 3486-3495
231. Ono A., and Freed E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U.S.A. 98 24 (2001) 13925-13930
232. Ono A., and Freed E.O. Role of lipid rafts in virus replication. Adv. Virus Res. 64 (2005) 311-358
233. Ono A., Demirov D., and Freed E.O. Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J. Virol. 74 11 (2000) 5142-5150
234. Ono A., Ablan S.D., Lockett S.J., Nagashima K., and Freed E.O. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 101 41 (2004) 14889-14894
235. Ono A., Waheed A.A., and Freed E.O. Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. Virology 360 (2007) 27-35
236. Owens C.M., Song B., Perron M.J., Yang P.C., Stremlau M., and Sodroski J. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J. Virol. 78 10 (2004) 5423-5437
237. Ozato K., Shin D.M., Chang T.H., and Morse III H.C. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 8 11 (2008) 849-860
238. Park S.H., and Opella S.J. Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs. Protein Sci. 16 10 (2007) 2205-2215
239. Parmegiani R.M., Loebenberg D., Antonacci B., Yarosh-Tomaine T., Scupp R., Wright J.J., Chiu P.J., and Miller G.H. Comparative in vitro and in vivo evaluation of N-D-ornithyl amphotericin B methyl ester, amphotericin B methyl ester, and amphotericin B. Antimicrob. Agents Chemother. 31 11 (1987) 1756-1760
240. Perez-Caballero D., Hatziioannou T., Yang A., Cowan S., and Bieniasz P.D. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J. Virol. 79 14 (2005) 8969-8978
241. Perno C.F., Moyle G., Tsoukas C., Ratanasuwan W., Gatell J., and Schechter M. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J. Med. Virol. 80 4 (2008) 565-576
242. Perron M.J., Stremlau M., Song B., Ulm W., Mulligan R.C., and Sodroski J. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. U.S.A. 101 32 (2004) 11827-11832
243. Perron M.J., Stremlau M., Lee M., Javanbakht H., Song B., and Sodroski J. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J. Virol. 81 5 (2007) 2138-2148
244. Pery E., Rajendran K.S., Brazier A.J., and Gabuzda D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83 5 (2009) 2374-2381
245. Pettit S.C., Moody M.D., Wehbie R.S., Kaplan A.H., Nantermet P.V., Klein C.A., and Swanstrom R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68 12 (1994) 8017-8027
246. Pettit S.C., Henderson G.J., Schiffer C.A., and Swanstrom R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76 20 (2002) 10226-10233
247. Pickl W.F., Pimentel-Muinos F.X., and Seed B. Lipid rafts and pseudotyping. J. Virol. 75 15 (2001) 7175-7183
248. Pike L.J. Rafts defined: a report on the keystone symposium on lipid rafts and cell function. J. Lipid Res. 47 7 (2006) 1597-1598
249. Poeschla E.M. Integrase, LEDGF/p75 and HIV replication. Cell Mol. Life Sci. 65 9 (2008) 1403-1424
250. Popik W., Alce T.M., and Au W.C. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J. Virol. 76 10 (2002) 4709-4722
251. Pornillos O., Alam S.L., Davis D.R., and Sundquist W.I. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat. Struct. Biol. 9 11 (2002) 812-817
252. Pornillos O., Alam S.L., Rich R.L., Myszka D.G., Davis D.R., and Sundquist W.I. Structure and functional interactions of the Tsg101 UEV domain. EMBO J. 21 10 (2002) 2397-2406
253. Pornillos O., Ganser-Pornillos B.K., Kelly B.N., Hua Y., Whitby F.G., Stout C.D., Sundquist W.I., Hill C.P., and Yeager M. X-ray structures of the hexameric building block of the HIV capsid. Cell 137 7 (2009) 1282-1292
254. Probasco J.C., Spudich S.S., Critchfield J., Lee E., Lollo N., Deeks S.G., and Price R.W. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology 71 7 (2008) 521-524
255. Puri A., and Blumenthal R. HIV type 1 entry correlates with plasma membrane microdomain lateral assemblies of receptors: implications in HIV/AIDS treatment. J. Viral Entry 3 (2008) 10-20
256. Rabson A.B., and Graves B.J. Synthesis and processing of viral RNA. In: Coffin J.M., Hughes S.H., and Varmus H.E. (Eds). Retroviruses (1997), Cold Spring Harbor Laboratory Press
257. Reicin A.S., Ohagen A., Yin L., Hoglund S., and Goff S.P. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J. Virol. 70 12 (1996) 8645-8652
258. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G., and Ballabio A. The tripartite motif family identifies cell compartments. EMBO J. 20 9 (2001) 2140-2151
259. Rice W.G., Schaeffer C.A., Harten B., Villinger F., South T.L., Summers M.F., Henderson L.E., Bess Jr. J.W., Arthur L.O., McDougal J.S., et al. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 361 6411 (1993) 473-475
260. Rice W.G., Supko J.G., Malspeis L., Buckheit Jr. R.W., Clanton D., Bu M., Graham L., Schaeffer C.A., Turpin J.A., Domagala J., Gogliotti R., Bader J.P., Halliday S.M., Coren L., Sowder II R.C., Arthur L.O., and Henderson L.E. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270 5239 (1995) 1194-1197
261. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., and Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 323 5919 (2009) 1304-1307
262. Richter S.N., and Palu G. Inhibitors of HIV-1 Tat-mediated transactivation. Curr. Med. Chem. 13 11 (2006) 1305-1315
263. Ritter Jr. G.D., Yamshchikov G., Cohen S.J., and Mulligan M.J. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J. Virol. 70 4 (1996) 2669-2673
264. Rold C.J., and Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog. 4 5 (2008) e1000074
265. Rong L., Zhang J., Lu J., Pan Q., Lorgeoux R.P., Aloysius C., Guo F., Liu S.L., Wainberg M.A., and Liang C. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 83 15 (2009) 7536-7546
266. Rose S., Hensley D.J., O'Shannessy J., Culp C., Debouck C., and Chaiken I. Characterisation of HIV-1 p24 self-association using affinity chromatography. Proteins 13 (1992) 112-119
267. Roux K.H., and Taylor K.A. AIDS virus envelope spike structure. Curr. Opin. Struct. Biol. 17 2 (2007) 244-252
268. Saad J.S., Miller J., Tai J., Kim A., Ghanam R.H., and Summers M.F. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl. Acad. Sci. U.S.A. 103 30 (2006) 11364-11369
269. Saad J.S., Ablan S.D., Ghanam R.H., Kim A., Andrews K., Nagashima K., Soheilian F., Freed E.O., and Summers M.F. Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J. Mol. Biol. 382 2 (2008) 434-447
270. Sakalian M., McMurtrey C.P., Deeg F.J., Maloy C.W., Li F., Wild C.T., and Salzwedel K. 3-o-(3′,3′-Dimethysuccinyl)betulinic acid inhibits maturation of the human immunodeficiency virus type 1 gag precursor assembled in vitro. J. Virol. 80 12 (2006) 5716-5722
271. Sakuma R., Mael A.A., and Ikeda Y. Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J. Virol. 81 18 (2007) 10201-10206
272. Sakuma R., Noser J.A., Ohmine S., and Ikeda Y. Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G. Gene Ther. 14 2 (2007) 185-189
273. Salzwedel K., Martin D.E., and Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 9 3 (2007) 162-172
274. Salzwedel K., Reddick M., Matallana C., Finnegan C., Adamson C., Sakalian M., Stanley D., Martin D., McCallister S., Freed E., and Allaway G. Role of Gag polymorphisms in HIV-1 sensitivity to the maturation inhibitor bevirimat. XVII International HIV Drug Resistance Workshop. Sitges, Spain (2008)
275. Salzwedel K., Hamy F., Louvel S., Sakalian M., Reddick M., Finnegan C., Martin D., McCallister S., Klimkait T., and Allaway G. Suceptibility of diverse HIV-1 patient isolates to the maturation inhibitor bevirimat (MPC-4326) is determined by clade-specific polymorphisms in Gag CA-SP1. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada (2009)
276. Santiago M.L., Montano M., Benitez R., Messer R.J., Yonemoto W., Chesebro B., Hasenkrug K.J., and Greene W.C. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321 5894 (2008) 1343-1346
277. Sarafianos S.G., Das K., Tantillo C., Clark Jr. A.D., Ding J., Whitcomb J.M., Boyer P.L., Hughes S.H., and Arnold E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J. 20 6 (2001) 1449-1461
278. Sarafianos S.G., Marchand B., Das K., Himmel D.M., Parniak M.A., Hughes S.H., and Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385 3 (2009) 693-713
279. Sato K., Yamamoto S.P., Misawa N., Yoshida T., Miyazawa T., and Koyanagi Y. Comparative study on the effect of human BST-2/Tetherin on HIV-1 release in cells of various species. Retrovirology 6 (2009) 53
280. Sawyer S.L., Wu L.I., Emerman M., and Malik H.S. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U.S.A. 102 8 (2005) 2832-2837
281. Sayah D.M., Sokolskaja E., Berthoux L., and Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430 6999 (2004) 569-573
282. Schito M.L., Goel A., Song Y., Inman J.K., Fattah R.J., Rice W.G., Turpin J.A., Sher A., and Appella E. In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model. AIDS Res. Hum. Retroviruses 19 2 (2003) 91-101
283. Scholz I., Arvidson B., Huseby D., and Barklis E. Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J. Virol. 79 3 (2005) 1470-1479
284. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., and Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110 4 (2002) 521-529
285. Schultz S.J., and Champoux J.J. RNase H activity: structure, specificity, and function in reverse transcription. Virus Res. 134 1-2 (2008) 86-103
286. Sebastian S., and Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2 (2005) 40
287. Shaw-Reid C.A., Munshi V., Graham P., Wolfe A., Witmer M., Danzeisen R., Olsen D.B., Carroll S.S., Embrey M., Wai J.S., Miller M.D., Cole J.L., and Hazuda D.J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278 5 (2003) 2777-2780
288. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 6898 (2002) 646-650
289. Shehu-Xhilaga M., Ablan S., Demirov D.G., Chen C., Montelaro R.C., and Freed E.O. Late domain-dependent inhibition of equine infectious anemia virus budding. J. Virol. 78 2 (2004) 724-732
290. Shi J., and Aiken C. Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 350 2 (2006) 493-500
291. Shibata R., Sakai H., Kawamura M., Tokunaga K., and Adachi A. Early replication block of human immunodeficiency virus type 1 in monkey cells. J. Gen. Virol. 76 Pt 11 (1995) 2723-2730
292. Shkriabai N., Datta S.A., Zhao Z., Hess S., Rein A., and Kvaratskhelia M. Interactions of HIV-1 Gag with assembly cofactors. Biochemistry 45 13 (2006) 4077-4083
293. Shun M.C., Raghavendra N.K., Vandegraaff N., Daigle J.E., Hughes S., Kellam P., Cherepanov P., and Engelman A. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 21 14 (2007) 1767-1778
294. Shvadchak V., Sanglier S., Rocle S., Villa P., Haiech J., Hibert M., Van Dorsselaer A., Mely Y., and de Rocquigny H. Identification by high throughput screening of small compounds inhibiting the nucleic acid destabilization activity of the HIV-1 nucleocapsid protein. Biochimie 91 7 (2009) 916-923
295. Simon J.H., Miller D.L., Fouchier R.A., Soares M.A., Peden K.W., and Malim M.H. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 17 5 (1998) 1259-1267
296. Simon V., Ho D.D., and Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368 9534 (2006) 489-504
297. Sklar P.A., Masur H., Grubb J.R., Voell J., Witek J., Ono A., Freed E.O., and Maldarelli F. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 19 10 (2005) 1109-1111
298. Smith P.F., Ogundele A., Forrest A., Wilton J., Salzwedel K., Doto J., Allaway G.P., and Martin D.E. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 51 10 (2007) 3574-3581
299. Somasunderam A., Ferguson M.R., Rojo D.R., Thiviyanathan V., Li X., O'Brien W.A., and Gorenstein D.G. Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 44 30 (2005) 10388-10395
300. Song Y., Goel A., Basrur V., Roberts P.E., Mikovits J.A., Inman J.K., Turpin J.A., Rice W.G., and Appella E. Synthesis and biological properties of amino acid amide ligand-based pyridinioalkanoyl thioesters as anti-HIV agents. Bioorg. Med. Chem. 10 5 (2002) 1263-1273
301. Stephens E.B., McCormick C., Pacyniak E., Griffin D., Pinson D.M., Sun F., Nothnick W., Wong S.W., Gunderson R., Berman N.E., and Singh D.K. Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques. Virology 293 2 (2002) 252-261
302. Sticht J., Humbert M., Findlow S., Bodem J., Muller B., Dietrich U., Werner J., and Krausslich H.G. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 12 8 (2005) 671-677
303. Stoddart C.A., Joshi P., Sloan B., Bare J.C., Smith P.C., Allaway G.P., Wild C.T., and Martin D.E. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One 2 11 (2007) e1251
304. Stoye J.P., and Yap M.W. Chance favors a prepared genome. Proc. Natl. Acad. Sci. U.S.A. 105 9 (2008) 3177-3178
305. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 6977 (2004) 848-853
306. Stremlau M., Perron M., Welikala S., and Sodroski J. Species-specific variation in the B30.2 (SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J. Virol. 79 5 (2005) 3139-3145
307. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., Diaz-Griffero F., Anderson D.J., Sundquist W.I., and Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U.S.A. 103 14 (2006) 5514-5519
308. Sutherland H.G., Newton K., Brownstein D.G., Holmes M.C., Kress C., Semple C.A., and Bickmore W.A. Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal transformations. Mol. Cell Biol. 26 19 (2006) 7201-7210
309. Suzuki Y., and Craigie R. The road to chromatin-nuclear entry of retroviruses. Nat. Rev. Microbiol. 5 3 (2007) 187-196
310. Svarovskaia E.S., Cheslock S.R., Zhang W.H., Hu W.S., and Pathak V.K. Retroviral mutation rates and reverse transcriptase fidelity. Front. Biosci. 8 (2003) d117-d134
311. Swanstrom R., and Wills J.W. Synthesis, assembly and processing of viral proteins. In: Coffin J.M., Hughes S.H., and Varmus H.E. (Eds). Retroviruses (1997), Cold Spring Harbor Laboratory Press
312. Tang S., Murakami T., Agresta B.E., Campbell S., Freed E.O., and Levin J.G. Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J. Virol. 75 19 (2001) 9357-9366
313. Tang C., Loeliger E., Kinde I., Kyere S., Mayo K., Barklis E., Sun Y., Huang M., and Summers M.F. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327 5 (2003) 1013-1020
314. Tang C., Loeliger E., Luncsford P., Kinde I., Beckett D., and Summers M.F. Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc. Natl. Acad. Sci. U.S.A. 101 2 (2004) 517-522
315. Tavassoli A., Lu Q., Gam J., Pan H., Benkovic S.J., and Cohen S.N. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. ACS Chem. Biol. 3 12 (2008) 757-764
316. Temesgen Z., Cainelli F., Poeschla E.M., Vlahakis S.A., and Vento S. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect. Dis. 6 8 (2006) 496-507
317. Ternois F., Sticht J., Duquerroy S., Krausslich H.G., and Rey F.A. The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nat. Struct. Mol. Biol. 12 8 (2005) 678-682
318. Tisdale M., Schulze T., Larder B.A., and Moelling K. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J. Gen. Virol. 72 Pt 1 (1991) 59-66
319. Towers G.J. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4 (2007) 40
320. Towers G., Bock M., Martin S., Takeuchi Y., Stoye J.P., and Danos O. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. U.S.A. 97 22 (2000) 12295-12299
321. Towers G.J., Hatziioannou T., Cowan S., Goff S.P., Luban J., and Bieniasz P.D. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9 9 (2003) 1138-1143
322. Tramontano E., Esposito F., Badas R., Di Santo R., Costi R., and La Colla P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res. 65 2 (2005) 117-124
323. Tritch R.J., Cheng Y.E., Yin F.H., and Erickson-Viitanen S. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J. Virol. 65 2 (1991) 922-930
324. Turner K.B., Hagan N.A., and Fabris D. Inhibitory effects of archetypical nucleic acid ligands on the interactions of HIV-1 nucleocapsid protein with elements of Psi-RNA. Nucleic Acids Res. 34 5 (2006) 1305-1316
325. Turpin J.A., Song Y., Inman J.K., Huang M., Wallqvist A., Maynard A., Covell D.G., Rice W.G., and Appella E. Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J. Med. Chem. 42 1 (1999) 67-86
326. Van Baelen K., Salzwedel K., Rondelez E., Van Eygen V., De Vos S., Verheyen A., Steegen K., Verlinden Y., Allaway G.P., and Stuyver L.J. HIV-1 susceptibility to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag SP1. Antimicrob. Agents Chemother. (2009)
327. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., and Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3 4 (2008) 245-252
328. Vandegraaff N., and Engelman A. Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev. Mol. Med. 9 6 (2007) 1-19
329. Varthakavi V., Smith R.M., Bour S.P., Strebel K., and Spearman P. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. U.S.A. 100 25 (2003) 15154-15159
330. Vogt V.M. Proteolytic processing and particle maturation. Curr. Top. Microbiol. Immunol. 214 (1996) 95-131
331. von Schwedler U.K., Stemmler T.L., Klishko V.Y., Li S., Albertine K.H., Davis D.R., and Sundquist W.I. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17 6 (1998) 1555-1568
332. von Schwedler U.K., Stray K.M., Garrus J.E., and Sundquist W.I. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J. Virol. 77 9 (2003) 5439-5450
333. Waheed A.A., and Freed E.O. Lipids and membrane microdomains in HIV-1 replication. Virus Res. (2009)
334. Waheed A.A., Ablan S.D., Mankowski M.K., Cummins J.E., Ptak R.G., Schaffner C.P., and Freed E.O. Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J. Biol. Chem. 281 39 (2006) 28699-28711
335. Waheed A.A., Ablan S.D., Roser J.D., Sowder R.C., Schaffner C.P., Chertova E., and Freed E.O. HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease. Proc. Natl. Acad. Sci. U.S.A. 104 20 (2007) 8467-8471
336. Waheed A.A., Ablan S.D., Soheilian F., Nagashima K., Ono A., Schaffner C.P., and Freed E.O. Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence. J. Virol. 82 19 (2008) 9776-9781
337. Warrilow D., and Harrich D. HIV-1 replication from after cell entry to the nuclear periphery. Curr. HIV Res. 5 3 (2007) 293-299
338. Welker R., Hohenberg H., Tessmer U., Huckhagel C., and Krausslich H.G. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J. Virol. 74 3 (2000) 1168-1177
339. Wendeler M., Lee H.F., Bermingham A., Miller J.T., Chertov O., Bona M.K., Baichoo N.S., Ehteshami M., Beutler J., O'Keefe B.R., Gotte M., Kvaratskhelia M., and Le Grice S. Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem. Biol. 3 10 (2008) 635-644
340. Wiegers K., Rutter G., Kottler H., Tessmer U., Hohenberg H., and Krausslich H.G. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72 4 (1998) 2846-2854
341. Wilk T., Gross I., Gowen B.E., Rutten T., de Haas F., Welker R., Krausslich H.G., Boulanger P., and Fuller S.D. Organization of immature human immunodeficiency virus type 1. J. Virol. 75 2 (2001) 759-771
342. Wills J.W., and Craven R.C. Form, function, and use of retroviral gag proteins. AIDS 5 (1991) 639-654
343. Worthylake D.K., Wang H., Yoo S., Sundquist W.I., and Hill C.P. Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution. Acta Crystallogr. D: Biol. Crystallogr. 55 Pt 1 (1999) 85-92
344. Wright E.R., Schooler J.B., Ding H.J., Kieffer C., Fillmore C., Sundquist W.I., and Jensen G.J. Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J. 26 8 (2007) 2218-2226
345. Wu X., Anderson J.L., Campbell E.M., Joseph A.M., and Hope T.J. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U.S.A. 103 19 (2006) 7465-7470
346. Xiao Z., Ehrlich E., Luo K., Xiong Y., and Yu X.F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21 1 (2007) 217-222
347. Xu L., Yang L., Moitra P.K., Hashimoto K., Rallabhandi P., Kaul S., Meroni G., Jensen J.P., Weissman A.M., and D'Arpa P. BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5delta. Exp. Cell Res. 288 1 (2003) 84-93
348. Yamauchi K., Wada K., Tanji K., Tanaka M., and Kamitani T. Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J. 275 7 (2008) 1540-1555
349. Yang W., Lee J.Y., and Nowotny M. Making and breaking nucleic acids: two-Mg2+-ion catalysis and substrate specificity. Mol. Cell 22 1 (2006) 5-13
350. Yap M.W., Nisole S., Lynch C., and Stoye J.P. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 101 29 (2004) 10786-10791
351. Yap M.W., Nisole S., and Stoye J.P. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 15 1 (2005) 73-78
352. Yap M.W., Dodding M.P., and Stoye J.P. Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J. Virol. 80 8 (2006) 4061-4067
353. Yap M.W., Mortuza G.B., Taylor I.A., and Stoye J.P. The design of artificial retroviral restriction factors. Virology 365 2 (2007) 302-314
354. Yeager M., Wilson-Kubalek E.M., Weiner S.G., Brown P.O., and Rein A. Supramolecular organisation of immature and mature murine leukemia virus revealed by electron cryo-microscopy: implications for retroviral assembly mechansims. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 7299-7304
355. Yebra G., and Holgun A. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants. Antiviral Ther. 13 8 (2008) 1083-1085
356. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 5647 (2003) 1056-1060
357. Yu F., Liu X., Zhan P., and De Clercq E. Recent advances in the research of HIV-1 RNase H inhibitors. Mini Rev. Med. Chem. 8 12 (2008) 1243-1251
358. Zhang H., Zhao Q., Bhattacharya S., Waheed A.A., Tong X., Hong A., Heck S., Curreli F., Goger M., Cowburn D., Freed E.O., and Debnath A.K. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J. Mol. Biol. 378 3 (2008) 565-580
359. Zhou J., Chen C.H., and Aiken C. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3′,3′-dimethylsuccinyl}-betulinic acid. Retrovirology 1 1 (2004) 15
360. Zhou J., Yuan X., Dismuke D., Forshey B.M., Lundquist C., Lee K.H., Aiken C., and Chen C.H. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J. Virol. 78 2 (2004) 922-929
361. Zhou J., Huang L., Hachey D.L., Chen C.H., and Aiken C. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J. Biol. Chem. 280 51 (2005) 42149-42155
362. Zhou J., Chen C.H., and Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J. Virol. 80 24 (2006) 12095-12101